Evaluation of the adjuvant activity of propranolol, a beta-adrenergic receptor antagonist, on efficacy of a malaria vaccine model in BALB/c mice

We have previously shown the adjuvant activity of propranolol (PRP) (a beta-adrenergic
receptor antagonist) using a vaccine model for Salmonella typhimurium. In this study PRP was
used as an adjuvant in combination with Plasmodium berghei (P. berghei) whole blood stage
(PWBS) antigens.
BALB/c mice were immunized three times with a 2-week interval, either PWBS vaccine
alone or in combination with the adjuvant alum or propranolol. The control group received
phosphate buffered saline. Evaluation of the cellular and humoral immunity was performed
by measurement of interferon (IFN)--, tumor necrosis factor (TNF)-., lymphocyte
proliferation, total IgG and IgG2a in the control and immunized groups. Furthermore,
Clinical evaluations were carried out by analyze survival rate and parasitemia of the mice.
Our results showed that the mice immunized with propranolol induced higher levels of
antibody, IFN-- and TNF-. as well as stronger lymphocyte proliferative responses compared
with other groups. This resulted in improved protective immunity against Plasmodium berghei.
Administration of the PRP as an adjuvant in combination with the PWBS Antigen
vaccine can shift the immune responses to a T helper1 pattern and enhance the protective
immunity.